stockrow
Friday 6 November 2026
Export CAI’s income statement to Excel — free account
Caris Life Sciences,�Inc.
Caris Life Sciences,�Inc.’s revenue for fiscal 2025 (year ended December 2025) was $812.0 million, up 97.0% from fiscal 2024.
- Revenue
- +27.0%
- EPS
- −40.3%
- Free cash flow
- −140.2%
- Total debt
- +4.46%
Quarter to September 2026, against a year earlier
24.78
1.25
−4.80%
Follow CAI
Alert me
Caris Life Sciences,�Inc. (CAI) Free cash flow margin
Caris Life Sciences,�Inc.'s free cash flow margin over the twelve months to 30 September 2026 was 8.00%, down 0.2 percentage points from fiscal 2025 (8.24%). That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 8.24% | 69.77 |
| FY2024 | −61.5% | 35.95 |
| FY2023 | −97.5% | — |
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| KRYS Krystal Biotech, Inc. compare | 66.0% |
| PTGX Protagonist Therapeutics, Inc. compare | 46.3% |
| CAI Caris Life Sciences,�Inc. | 8.00% |
| TGTX TG Therapeutics, Inc. compare | 2.17% |
| SYRE Spyre Therapeutics, Inc. compare | 0.00% |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −11.8% |
| TWST Twist Bioscience Corporation compare | −22.2% |
| IBRX ImmunityBio, Inc. compare | −173.8% |
| CYTK Cytokinetics, Incorporated compare | −519.5% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on CAI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement